MONTREAL, June 19, 2025 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (“ Cannara ”, “the Company ”, “ us ” or “ we ”) (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB0), a vertically integrated producer of premium-grade cannabis products at disruptive prices with two mega facilities based in Québec spanning over 1,650,000 sq. ft, today announced that it will host a webcast investor presentation on Wednesday, June 25, 2025, at 2:00 PM ET.... Read More

MONTREAL, June 18, 2025 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (“Cannara”, “the Company”, “us” or “we”) (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB0), a vertically integrated producer of premium-grade cannabis products at disruptive prices with two mega facilities based in Québec spanning over 1,650,000 sq. ft., is proud to announce that in recognition of its continued commitment to product excellence and innovation, Cannara was... Read More

Record Revenue: Net revenues of $26.6 million in Q2 2025, a 35% increase compared to $19.7 million in Q2 2024, driven by national brand growth and product innovation. Record Profitability: Gross profit before fair value adjustments rose 52% to $10.8 million in Q2 2025 from $7.1 million in Q2 2024, with gross margins improving to 41%. Strong Adjusted EBITDA: Delivered sixteenth consecutive quarter of positive Adjusted EBITDA,... Read More

MONTREAL, April 16, 2025 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (“ Cannara ”, “the Company ”, “ us ” or “ we ”) (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB0), a vertically integrated producer of premium-grade cannabis and derivative product offerings at affordable prices with two mega facilities based in Québec spanning over 1,650,000 sq. ft., today announced that it will release its financial results for the second quarter... Read More

MONTREAL, March 24, 2025 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (“ Cannara ”, “the Company ”, “ us ” or “ we ”) (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB0), a vertically integrated producer of premium-grade cannabis and derivative product offerings at affordable prices with two mega facilities based in Québec spanning over 1,650,000 sq. ft., is pleased to announce the appointment of Mr. Justin Cohen to its board of directors... Read More

MONTREAL, March 06, 2025 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (“ Cannara ”, “the Company ”, “ us ” or “ we ”) (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB0), a vertically integrated producer of premium-grade cannabis and derivative product offerings at affordable prices with two mega facilities based in Québec spanning over 1,650,000 sq. ft., is pleased to announce it will be presenting at the Ventum Capital Markets Canadian... Read More

MONTREAL, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (“ Cannara ”, “the Company ”, “ us ” or “ we ”) (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB0), a vertically integrated producer of premium-grade cannabis and derivative product offerings at affordable prices with two mega facilities based in Québec spanning over 1,650,000 sq. ft., is pleased to announce the extension and related amendments to its existing credit... Read More

Record Revenue: Net revenues of $25.1 million in Q1 2025, a 29% increase compared to $19.5 million in Q1 2024, driven by strong demand for Cannara’s premium-grade cannabis products. Record Market Share: Achieved Canadian market share of 4.1% 1 , representing a 28% increase quarter over quarter, and 58% increase over the same period of prior year with gains across all licensed provinces. Robust Profitability: Gross profit... Read More

MONTREAL, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (“Cannara”, “the Company”, “us” or “we”) (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB0), a vertically integrated producer of premium-grade cannabis and derivative product offerings at affordable prices with two mega facilities based in Québec spanning over 1,650,000 sq. ft., that it will be relying on CSA Coordinated Blanket Order 51-913 for an exemption from the... Read More

MONTREAL, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (“Cannara”, “the Company”, “us” or “we”) (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB0), a vertically integrated producer of premium-grade cannabis and derivative product offerings at affordable prices with two mega facilities based in Quebec spanning over 1,650,000 sq. ft., today announced that it will host a webcast investor presentation on Thursday, December 19 th... Read More

Record Q4 and year-end total revenues of $23.4 million and $82.2 million, representing a 28% and 43% increase compared to the same periods in 2023. Robust growth in Q4 over Q3 2024, with total revenues increasing by 20%, operating income by 42%, Adjusted EBITDA 1 by 33%, net income by 184% and free cash flow 1 by 117%.... Read More

MONTREAL, Aug. 16, 2024 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (" Cannara " or the " Company ") (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB0), a vertically integrated producer of premium-grade cannabis and derivative product offerings at affordable prices with two mega facilities based in Quebec spanning over 1,650,000 sq. ft., today announced that the Company has achieved its highest national market share of 3.2% in July 2024... Read More

Gross cannabis revenues before excise taxes increased to $26.2 million in Q3 2024 from $20.6 million in Q3 2023, a $5.6 million or 27.6%, increase. Total revenues, net of excise taxes, increased to $19.5 million in Q3 2024 from $15.9 million in Q3 2023, a $3.6 million or 22.6% increase. Delivered a thirteenth consecutive quarter of positive Adjusted EBITDA 1 of $2.8 million. All financial results are reported in Canadian... Read More

Net revenue, increased to $19.7 million in Q2 2024 from $13.0 million in Q2 2023, a 51.0% increase. Gross profit, before fair value adjustments, increased to $7.1 million in Q2 2024 from $4.0 million in Q2 2023, a 77.2% increase. Delivered a twelfth consecutive quarter of positive Adjusted EBITDA 1 of $3.5 million . All... Read More

Record Q1 net revenues of $19.5 million , representing an 89% increase compared to the $10.3 million of net revenues generated in Q1 2023 Q1 operating income of $3.4 million , representing an 201% increase compared to the $1.1 million of operating income generated in Q1 2023 Delivered an eleventh consecutive quarter of... Read More

MONTREAL , Jan. 8, 2024 /CNW/ - Cannara Biotech Inc. (" Cannara " or the " Company ") (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB), a vertically integrated producer of premium-grade cannabis and derivative product offerings at affordable prices with two mega facilities based in Quebec spanning over 1,650,000 sq. ft., today announced it has retained Independent Trading Group ("ITG") to provide market making services in accordance... Read More

MONTREAL , Dec. 13, 2023 /CNW/ - Cannara Biotech Inc. (" Cannara " or the " Company ") (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB), a vertically integrated producer of premium-grade cannabis and derivative product offerings at affordable prices with two mega facilities based in Quebec spanning over 1,650,000 sq. ft., today announced that it will host the Company's annual general meeting of shareholders on January 25th, 2024 at... Read More

MONTREAL , Dec. 11, 2023 /CNW/ - Cannara Biotech Inc. ("Cannara" or the "Company") (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB), a vertically integrated producer of premium-grade cannabis and derivative products with one of the largest indoor cannabis cultivation facilities in Canada, and the largest in Quebec, today announced that it will host a webcast investor presentation on Thursday, December 14 th , 2023, at 2:00 PM ET.... Read More

Record Q4 and year end net revenues of $18.3 million and $57.6 million , representing a 53% and 60% increase compared to the same periods of 2022 Sequentially, Q4 showed significant growth over Q3 2023 with higher net revenues by 15%, operating income by 36%, Adjusted EBITDA by 26% and net income by 58% Delivered a tenth consecutive quarter of positive Adjusted EBITDA of $4.9 million Generated a record quarterly net income... Read More

Three- and nine-month net revenue were $15.9 million and $39 .3 million, a 57% and 63% increase compared to the same periods of prior year Delivered its ninth consecutive quarter of positive Adjusted EBITDA of $3.9 million, a 129% increase compared to Q3 2022 Generated Q3 2023 net income of $2.9 million and free cash flow of $3.2 million Reached an annual production capacity of 30,500 kg of premium-grade cannabis per year,... Read More

Montreal, Quebec--(Newsfile Corp. - May 23, 2023) - Cannara Biotech Inc (TSXV: LOVE) announced today that it will be presenting at the 13th Annual LD Micro Invitational at the Luxe Sunset Boulevard Hotel, California on June 6th-8th, 2023. The event is expected to feature 150+ companies, presenting in half-hour increments, as well as private 1:1 meetings. Cannara Biotech Inc is scheduled to present on June 7th at 3:00 PM PT.... Read More

MONTREAL , May 11, 2023 /PRNewswire/ - Cannara Biotech Inc. (" Cannara " or the " Company ") (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB), a vertically integrated producer of premium-grade cannabis and derivative product offerings at affordable prices with two mega facilities based in Québec spanning over 1,650,000 sq. ft., today announced its upcoming participation at Canaccord Genuity's 7 th annual global cannabis conference.... Read More

MONTREAL , May 4, 2023 /CNW/ - Cannara Biotech Inc. (" Cannara " or the " Company ") (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB), a vertically integrated producer of premium-grade cannabis and derivative product offerings at affordable prices with two mega facilities based in Québec spanning over 1,650,000 sq. ft., announced today that they have raised an additional $10 million of credit facilities from its lead bank, BMO... Read More

MONTREAL , April 25, 2023 /CNW/ - Cannara Biotech Inc. (" Cannara " or the " Company ") (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB), a vertically integrated producer of premium-grade cannabis and derivative product offerings at affordable prices with two mega facilities based in Québec spanning over 1,650,000 sq. ft., today announced that it will host a webcast investor presentation on Thursday, May 4 th , 2023, at 2:00 PM ET.... Read More

Six-month net revenues of $23.4 million , a 67% increase compared to first half 2022 Delivered its eighth consecutive quarter of positive Adjusted EBITDA of $3.2M, a 1500% increase compared to Q2 2022 Continued to increase growing capacity to meet customer demand by activating an additional growing zone in its expanding... Read More

MONTREAL , Feb. 28, 2023 /CNW/ - Cannara Biotech Inc. (" Cannara " or the " Company ") (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB), a vertically integrated producer of premium-grade cannabis and derivative products with one of the largest indoor cannabis cultivation facilities in Canada and the largest in Quebec , today announced that it has entered into an automatic share purchase plan (" ASPP ") with Raymond James Ltd. ("... Read More

MONTREAL , Feb. 10, 2023 /CNW/ - Cannara Biotech Inc. (" Cannara " or the " Company ") (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB), a vertically integrated producer of premium-grade cannabis and derivative product offerings at affordable prices with two mega facilities based in Québec spanning over 1,650,000 sq. ft., announced today that further to its news release dated January 11, 2023 , the Company held its annual shareholder... Read More

Company recorded $10.3 million in quarterly revenue; a 57% increase compared to Q1 2022 Delivered its seventh consecutive quarter of positive Adjusted EBITDA of $1.7M and reported positive net income for a second consecutive quarter Continued to increase growing capacity to meet customer demand by activating new growing zone... Read More

MONTREAL , Jan. 12, 2023 /CNW/ - Cannara Biotech Inc . (" Cannara " or the " Company ") (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB), a vertically integrated producer of premium-grade cannabis and derivative products with two mega facilities based in Québec spanning over 1,650,000 sq. ft., today announces details of its proposal to consolidate all of the issued and outstanding common shares of the Company on the basis of ten (10)... Read More

MONTREAL , Nov. 30, 2022 /PRNewswire/ - Cannara Biotech Inc. (" Cannara " or the " Company ") (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB), a vertically integrated producer of premium-grade cannabis and derivative products with one of the largest indoor cannabis cultivation facilities in Canada and the largest in Quebec , today announced that the Company filed with the TSX Venture Exchange ("the "TSX-V") a Notice in respect of a... Read More

Company recorded a record high of $12 million in quarterly revenue (84% YoY increase) and Net Income of $2.6 million Full year revenues were $36 million , a 108% increase compared to 2021 Delivered its sixth consecutive quarter of positive Adjusted EBITDA of $2.5M , and $5.3M for fiscal year 2022 All financial results are... Read More

Cannara Biotech Inc. (" Cannara " or the " Company ") (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB), a Quebec -based, vertically integrated producer of premium-grade cannabis and derivative product offerings at affordable prices, announced today that it will be releasing 14 new SKU's of its premium-grade cannabis in Ontario and Quebec under the Company's flagship brands, Tribal, Nugz, and Orchid CBD brands. Brand Product Name... Read More

Cannara Biotech Inc. ("Cannara" or the "Company") (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB), a Quebec -based, vertically integrated producer of premium-grade cannabis and derivative product offerings at affordable prices, today announced its entry into the British Columbia (BC) market. In addition, the Company is also pleased to announce the launch of its first two premium product offerings in the vape and accessory categories.... Read More

Cannara Biotech Inc. (" Cannara " or the " Company ") (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB), a vertically integrated producer of premium-grade cannabis and derivative products with one of the largest indoor cannabis cultivation facilities in Canada and the largest in Quebec , announced that on August 31, 2022 , Derek Stern , a director and principle shareholder owning more than 10% of the issued and outstanding common... Read More

Cannara Biotech Inc . ("Cannara" or the "Company") (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB), a vertically integrated producer of premium-grade cannabis and derivative products with one of the largest indoor cannabis cultivation facilities in Canada , and the largest in Quebec , today announced that it will host a webcast investor presentation on Wednesday, August 17 th , 2022, at 2:00 PM ET . During the webcast, Nicholas... Read More

Agreement grants Cannara an exclusive license to use, sell and distribute Exotic Genetix branded products throughout Canada in addition to providing access to direct breeder's knowledge and insights on Exotic Genetix' cannabis strains Cannara Biotech Inc. ("Cannara" or the "Company") (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB), a... Read More

Company recorded a record high of $10.1 million in quarterly revenue and $24.1 million in year-to-date revenue, delivering its fifth consecutive quarter of positive Q3 2022 Adjusted EBITDA of $1.8M with net income of $1.4 million Valleyfield Facility continues to scale, and the Company now has 6 of its 24 growing zones in full... Read More

Cannara Biotech Inc. (" Cannara " or the " Company ") (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB), a vertically integrated producer of premium-grade cannabis and derivative products with two mega facilities based in Quebec spanning over 1,650,000 sq. ft., announced today that it has closed on a $50M credit facility led by BMO Commercial Banking. The credit facility, effective May 31, 2022 , includes a three-year term loan for $45... Read More

Cannara Biotech Inc. (" Cannara " or the " Company ") (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB), a vertically integrated producer of premium-grade cannabis and derivative products with two mega facilities based in Québec spanning over 1,650,000 sq. ft., today announced the Company's Chief Financial Officer, Nicholas Sosiak ,... Read More

Company recorded $7.4 million in quarterly revenues and delivers fourth consecutive quarter of positive Adjusted EBITDA while continuing to rapidly scale production capacity at the Valleyfield Facility Completed first harvest from the Valleyfield Facility with positive market feedback consistent with the quality of products... Read More

Strong execution leads to third consecutive quarter of positive Adjusted EBITDA Company recorded quarterly revenues of $6.6 million Growing operations initiated at new Valleyfield Facility All financial results are reported in Canadian dollars, unless otherwise stated. Cannara Biotech Inc. (" Cannara " or the " Company ")... Read More

Company invites individual and institutional investors, as well as advisors and analysts, to attend a real-time, interactive presentation on VirtualInvestorConferences.com Cannara Biotech Inc. (" Cannara " or the " Company ") (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB), a vertically integrated producer of premium-grade cannabis and... Read More

Fiscal 2021 revenues of $17.3 million , gross profit of $10.5 million or 61% and an Adjusted EBITDA of $1.5 million , strong indicators of Cannara's performance and successful operating strategy All financial results are reported in Canadian dollars, unless otherwise stated. Cannara Biotech Inc. (" Cannara " or the " Company... Read More

Refinancing will decrease the Company's overall debt servicing costs to 4.3% Cannara Biotech Inc. (" Cannara " or the " Company ") (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB), a vertically integrated producer of premium-grade cannabis and derivative products with two mega cultivation facilities based in Québec spanning over... Read More

10 000 plants to be propagated in the re-designed Valleyfield zones to replicate indoor growing conditions Cannara Biotech Inc. (" Cannara " or the " Company ") (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB), a vertically integrated producer of premium-grade cannabis and derivative products with two mega cultivation facilities based... Read More

Cannara Biotech Inc. ("Cannara" or the "Company") (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB), a vertically integrated producer of premium-grade cannabis and derivative products with two Quebec -based mega cultivation facilities spanning over 1,650,000 sq. ft., today announced it has received an amendment of its License from Health Canada, permitting the sale of Cannabis 2.0 products for which the Company intends to use to... Read More

Third quarter revenue of $7.2 million , gross profit of $4.4 million , and net income of $1.7 million showcases success of market strategy and operating model Cannara Biotech Inc. ( "Cannara" or the "Company" ) (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB), a vertically integrated producer of premium-grade cannabis and derivative... Read More

Cannara Biotech Inc. ( "Cannara" or the "Company" ) (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB), a vertically integrated producer of premium–grade cannabis and derivative products with two Quebec–based mega cultivation facilities spanning over 1,650,000 sq. ft., today announced that it has closed an additional $5 million private placement at an issue price per share of $0.18 , resulting in the issuance of 27,777,778 new common... Read More

Preliminary results from first commercial quarter in market show successful market launch in Quebec Cannara Biotech Inc. ( "Cannara" or the "Company" ) (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB), is pleased to announce preliminary unaudited revenue results for the three-month period ended May 31, 2021 , marking the retail debut... Read More

Newly built fully automated one million sq. ft. facility increases Company's capacity of premium-grade cannabis up to 125,000 kg annually Cannara Biotech Inc. (" Cannara " or the " Company ") (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB), a vertically integrated producer of premium-grade cannabis and derivative products with one of... Read More

Newly built fully automated one million sq. ft. facility increases Company's capacity of premium-grade cannabis up to 125,000 kg annually Cannara Biotech Inc. (" Cannara " or the " Company ") (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB), a vertically integrated producer of premium-grade cannabis and derivative products with one of... Read More

Significant second quarter revenue generation of $1.2 million and gross profit increase to $2.1 million showcases Cannara's positive trajectory Cannara Biotech Inc. (" Cannara " or the " Company ") (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB), a vertically integrated producer of indoor cannabis and derivative products with one of... Read More

TSXV market listing anticipated to improve visibility of Cannara among the investor community Cannara Biotech Inc. ("Cannara" or the "Company") (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB), a vertically integrated producer of premium-grade indoor cannabis and derivative products with one of the largest indoor cannabis cultivation facilities in Canada and the largest in Quebec , today announced its common shares will be listed on... Read More

Anticipated TSXV market listing coincides with the appointment of Nicholas Sosiak to CFO and retail market debut Cannara Biotech Inc. ("Cannara" or the "Company") (CSE: LOVE) (OTCQB: LOVFF) (FRA: 8CB), a vertically integrated Quebec -based producer of premium-grade indoor cannabis and derivative products with one of the... Read More

Cannara's three new brands – Tribal, Nugz and Orchid CBD Cannara Biotech Inc. ("Cannara" or the "Company") (CSE: LOVE) (OTCQB: LOVFF) (FRA: 8CB), a vertically integrated producer of indoor cannabis and derivative products with one of the largest indoor cannabis cultivation facilities in Canada and the largest in Quebec , today... Read More

- Expects to generate revenue from letter of intent with the Société québécoise du cannabis by end of February or early March 2021 - Cannara Biotech Inc. (" Cannara " or the " Company ") (CSE: LOVE) (OTCQB: LOVFF) (FRA: 8CB) is pleased to announce its financial results for the three-month period ended November 30, 2020 . Unless otherwise noted, all dollar amounts are expressed in Canadian dollars. Q1 2021 OPERATIONAL... Read More